| |
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now. 
|
|
Today’s Big NewsDec 17, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
| By Angus Liu Pfizer CEO Albert Bourla said he has developed "a good relation" with Trump's pick for HHS secretary, Robert F. Kennedy Jr., as the New York pharma assumes no material vaccine policy changes in the U.S. in 2025. |
|
|
|
By Gabrielle Masson In a day that already included discontinuations from Roche and Foghorn Therapeutics, Merck & Co. rounded out Monday with the termination of two late-stage cancer assets. |
By Andrea Park The ubiquity of GLP-1 agonists in popular culture may be negatively affecting patients’ perceptions and use of the medications for weight management, according to a new survey of doctors around the world. |
By Gabrielle Masson UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. |
|
Antibody-based therapies have transformed the treatment of many diseases, with biologics remaining at the cutting-edge of R&D today. Access this insightful resource today to explore the traditional technologies used for finding antibody hits, and the latest innovations helping to overcome the top challenges with legacy methods. Download now. 
|
|
By Conor Hale Boston Scientific said it has seen two reported patient deaths linked to the issue. |
By Kevin Dunleavy The FDA has sent complete response letters to Johnson & Johnson and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa. |
By Fraiser Kansteiner In the phase 2b trial, Sanofi and Teva's anti-TL1A antibody duvakitug met the mark in patients with ulcerative colitis and Crohn’s disease. The readout turns up the heat on a brewing rivalry with Merck and Roche, which are working on their own TL1A assets in similar indications. |
By Fraiser Kansteiner Current helmsman Bruce Cozadd plans to retire from his role at Jazz Pharmaceuticals in the next 12 months, the company said Monday. Jazz aims to complete its search for a CEO successor by the end of 2025, after which Cozadd will stay on board as the drugmaker's board chair. |
By Conor Hale The company said the feature has begun rolling out to Stelo customers through the smartphone app’s weekly insights feature, which delivers recommendations related to diet, sleep and exercise. |
By Zoey Becker Sandoz has agreed to pay another group of plaintiffs in the long-running price-fixing litigation it inherited from former parent company Novartis, marking a further step by the company to leave the "legacy" allegations behind. |
By James Waldron Three months after Biomea Fusion’s menin inhibitor was released from a clinical hold, the company has claimed a win in a phase 2 diabetes trial. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
